title: Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.
authors.affiliation: University of Pennsylvania Cancer Center, Philadelphia, USA. somerb@mail.med.upenn.edu
authors.forename: Bradley G
authors.initials: BG
authors.lastname: Somer
authors.forename: Donald E
authors.initials: DE
authors.lastname: Tsai
authors.forename: Lisa
authors.initials: L
authors.lastname: Downs
authors.forename: Barry
authors.initials: B
authors.lastname: Weinstein
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab